Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hole

Showing results (181-190 of 194) with videos related to

Pageof 20
Sort By:
Thorax|February 1, 1979
Cell-mediated immunity in operable bronchial carcinoma: the effect of injecting irradiated autologous tumour cells and BCGB H Stack, N McSwan, J M Stirling, et al.
Lancet (London, England)|July 31, 1998
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?A F Lever, D J Hole, C R Gillis, et al.
Journal of Medicinal Chemistry|January 11, 2013
Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activitiesHao Shao, Shenhua Shi, Shiliang Huang, et al.
Plos One|July 25, 2015
Quantitative Trait Loci Associated with the Tocochromanol (Vitamin E) Pathway in BarleyRyan C Graebner, Mitchell Wise, Alfonso Cuesta-Marcos, et al.
Hepatology (Baltimore, Md.)|February 23, 2023
Reply: The mucosal gut signature in primary sclerosing cholangitis before and after liver transplantation. Is the dysbiosis index really predictive for the recurrence of PSC?Mikal J Hole, Kristin K Jørgensen, Kristian Holm, et al.
Journal of Medicinal Chemistry|October 23, 2024
Targeting <i>Pf</i>CLK3 with Covalent Inhibitors: A Novel Strategy for Malaria TreatmentSkye B Brettell, Omar Janha, Abbey Begen, et al.
JHEP Reports : Innovation in Hepatology|April 8, 2026
Geography-independent mucosal microbiota alterations in primary sclerosing cholangitis persist after liver transplantationLukas Bajer, Petra Polakovicova, Marie Heczkova, et al.
European Journal of Clinical Nutrition|July 30, 2005
Empowering primary care to tackle the obesity epidemic: the Counterweight ProgrammeM McQuigg, J Brown, J Broom, et al.
Obesity Research & Clinical Practice|December 20, 2013
The Counterweight programme: Prevalence of CVD risk factors by body mass index and the impact of 10% weight changeM McQuigg, J E Brown, J Broom, et al.
Journal of Medicinal Chemistry|May 19, 2026
Discovery of a Novel Lung-Restricted ALK5 Inhibitor for the Treatment of Idiopathic Pulmonary FibrosisPaolo Ronchi, Daniela Pizzirani, Daniele Pala, et al.
Pageof 20

Showing results (181-190 of 194) with videos related to

Sort By:
Pageof 20
Thorax|February 1, 1979
Cell-mediated immunity in operable bronchial carcinoma: the effect of injecting irradiated autologous tumour cells and BCGB H Stack, N McSwan, J M Stirling, et al.
Lancet (London, England)|July 31, 1998
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?A F Lever, D J Hole, C R Gillis, et al.
Journal of Medicinal Chemistry|January 11, 2013
Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activitiesHao Shao, Shenhua Shi, Shiliang Huang, et al.
Plos One|July 25, 2015
Quantitative Trait Loci Associated with the Tocochromanol (Vitamin E) Pathway in BarleyRyan C Graebner, Mitchell Wise, Alfonso Cuesta-Marcos, et al.
Hepatology (Baltimore, Md.)|February 23, 2023
Reply: The mucosal gut signature in primary sclerosing cholangitis before and after liver transplantation. Is the dysbiosis index really predictive for the recurrence of PSC?Mikal J Hole, Kristin K Jørgensen, Kristian Holm, et al.
Journal of Medicinal Chemistry|October 23, 2024
Targeting <i>Pf</i>CLK3 with Covalent Inhibitors: A Novel Strategy for Malaria TreatmentSkye B Brettell, Omar Janha, Abbey Begen, et al.
JHEP Reports : Innovation in Hepatology|April 8, 2026
Geography-independent mucosal microbiota alterations in primary sclerosing cholangitis persist after liver transplantationLukas Bajer, Petra Polakovicova, Marie Heczkova, et al.
European Journal of Clinical Nutrition|July 30, 2005
Empowering primary care to tackle the obesity epidemic: the Counterweight ProgrammeM McQuigg, J Brown, J Broom, et al.
Obesity Research & Clinical Practice|December 20, 2013
The Counterweight programme: Prevalence of CVD risk factors by body mass index and the impact of 10% weight changeM McQuigg, J E Brown, J Broom, et al.
Journal of Medicinal Chemistry|May 19, 2026
Discovery of a Novel Lung-Restricted ALK5 Inhibitor for the Treatment of Idiopathic Pulmonary FibrosisPaolo Ronchi, Daniela Pizzirani, Daniele Pala, et al.
Pageof 20